MINNEAPOLIS, Jan. 8 /PRNewswire-FirstCall/ -- ATS Medical, Inc.
(Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery
products, announced today that it will participate at the 27th Annual J.P.
Morgan Healthcare Conference at the Westin St. Francis in San Francisco.
Michael Dale, President and CEO of ATS Medical, will present at 1:30 p.m.
Pacific Time on Thursday, January 15, 2009.

  (Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)

  Attendance at the conference is by invitation only. A live audio-only
webcast of the presentation will be broadcast via the Internet. Those
interested in listening to the webcast may access it at ATS Medical's website
at http://www.atsmedical.com. An archived replay of the presentation will
also be available approximately one hour following the live presentation at
http://www.atsmedical.com.


  About ATS Medical

  ATS Medical, Inc. is dedicated to 'Advancing The Standards' of cardiac
surgery through the development, manufacturing and marketing of innovative
products and services for the treatment of structural heart disease. ATS
Medical serves the cardiac surgery community by focusing on two distinct but
operationally synergistic market segments: heart valve disease therapy and
surgical ablation of cardiac arrhythmias.

  ATS was originally founded to develop the ATS Open Pivot(R) Heart Valve as
a new mechanical heart valve standard of care. Today the Open Pivot heart
valve is the preferred mechanical heart valve in many markets around the world
and the fastest growing mechanical prosthesis in the market. Building on this
legacy and addressing the largest market segment in heart valve therapy, the
ATS 3f(R) brand encompasses an innovative tissue heart valve portfolio to
address conventional open surgery requirements as well as the growing demand
for less invasive sutureless based procedures. The ATS 3f(R) portfolio
includes offerings at various stages including early product development,
pivotal clinical trials, and market commercialization. Completing the
portfolio in heart valve therapy is the ATS Simulus(R) annuloplasty product
line. Simulus products assist the surgeon in repairing a patient's native
heart valve as an alternative to replacement. Continuing ATS Medical's focus
on serving the cardiac surgery community are the ATS CryoMaze(TM) products for
surgical cryoablation of cardiac arrhythmias. ATS CryoMaze(TM) products are
used by surgeons to treat patients suffering from cardiac arrhythmias, the
largest and fastest growing form of structural heart disease in populations
over 60 years of age. The ATS Medical web site is http://www.atsmedical.com.


SOURCE ATS Medical, Inc.